Author + information
- Received August 3, 2016
- Revision received October 4, 2016
- Accepted October 6, 2016
- Published online November 6, 2017.
- Arnav Kumar, MBBSa,
- Kimi Sato, MDa,
- Edlira Yzeiraj, DO, MSa,
- Jorge Betancor, MDa,
- Lin Lin, PhDa,
- Balaji K. Tamarappoo, MD, PhDb,
- Deborah H. Kwon, MDa,
- Rory Hachamovitch, MD, MSca and
- Allan L. Klein, MDa,∗ ()
- aHeart and Vascular Institute, Center for the Diagnosis and Treatment of Pericardial Diseases, Cleveland Clinic, Cleveland, Ohio
- bHeart Institute, Cedars Sinai Medical Center, Los Angeles, California
- ↵∗Address for correspondence:
Dr. Allan L. Klein, Heart and Vascular Institute, Center for the Diagnosis and Treatment of Pericardial Diseases, Cleveland Clinic, 9500 Euclid Avenue, Desk J1-5, Cleveland, Ohio 44195.
Objectives The aim of this study was to evaluate the prognostic value of quantitative assessment of pericardial delayed hyperenhancement (DHE) among patients with recurrent pericarditis (RP).
Background Pericardial DHE on cardiac magnetic resonance may persist beyond the acute phase of pericarditis, suggesting continued pericardial inflammation.
Methods This is a retrospective cohort study of 159 patients with RP who underwent DHE imaging and had a follow-up period of more than 6 months. Pericardial inflammation was quantified on short-axis DHE sequences by contouring the pericardium, selecting normal septal myocardium as a reference region, and then quantifying the pericardial signal that was >6 SD above the reference. Our primary outcome was clinical remission; secondary outcomes were time to recurrence and recurrence rate.
Results The mean age of our patients was 46 ± 14 years, and 52% were women. During a median follow-up period of 23 months (interquartile range: 15 to 34 months), 32 (20%) patients achieved clinical remission. In the multivariable Cox proportional hazards model, lower quantitative pericardial DHE (hazard ratio: 0.77; 95% confidence interval: 0.64 to 0.93; p = 0.008) was independently associated with clinical remission. When added to background clinical and laboratory variables, quantitative pericardial DHE had incremental prognostic value over baseline clinical and laboratory variables (integrated discrimination improvement: 8%; net reclassification improvement: 36%). Furthermore, patients with a higher quantitative DHE had shorter time to subsequent recurrence (p = 0.012) and had a higher recurrence rate at 6 months (p = 0.026).
Conclusions Quantitative assessment of pericardial DHE was associated with clinical outcomes among patients with RP and provided incremental information regarding the clinical course of patients with RP.
All authors have reported that they have no relationships relevant to the contents of this paper to disclose. Drs. Kumar and Sato contributed equally to this work.
- Received August 3, 2016.
- Revision received October 4, 2016.
- Accepted October 6, 2016.
- 2017 American College of Cardiology Foundation